Enhabit (EHAB) Projected to Post Earnings on Wednesday

Enhabit (NYSE:EHAB) is expected to be posting its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect Enhabit to post earnings of $0.12 per share and revenue of $267.0750 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 9:00 AM ET.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.03. Enhabit had a positive return on equity of 2.72% and a negative net margin of 12.84%.The firm had revenue of $266.10 million for the quarter, compared to analysts’ expectations of $263.39 million. On average, analysts expect Enhabit to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Enhabit Trading Down 0.8%

Shares of Enhabit stock opened at $8.52 on Wednesday. The company’s 50-day moving average price is $8.06 and its 200-day moving average price is $8.35. The company has a current ratio of 1.57, a quick ratio of 1.57 and a debt-to-equity ratio of 0.79. Enhabit has a 12-month low of $6.47 and a 12-month high of $10.90. The company has a market cap of $431.63 million, a price-to-earnings ratio of -3.19 and a beta of 1.69.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on EHAB. UBS Group lowered their target price on shares of Enhabit from $10.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enhabit in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.67.

Insiders Place Their Bets

In other news, CFO Ryan Solomon purchased 10,000 shares of the company’s stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $7.64 per share, with a total value of $76,400.00. Following the completion of the purchase, the chief financial officer directly owned 193,468 shares in the company, valued at approximately $1,478,095.52. This trade represents a 5.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Enhabit

Institutional investors have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership raised its holdings in shares of Enhabit by 96.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 640,074 shares of the company’s stock valued at $6,170,000 after buying an additional 314,401 shares in the last quarter. Qube Research & Technologies Ltd grew its position in Enhabit by 36.3% during the second quarter. Qube Research & Technologies Ltd now owns 516,828 shares of the company’s stock valued at $4,982,000 after acquiring an additional 137,765 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Enhabit by 115.6% during the first quarter. AQR Capital Management LLC now owns 215,341 shares of the company’s stock worth $1,867,000 after acquiring an additional 115,456 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Enhabit by 38.2% in the 2nd quarter. Bank of America Corp DE now owns 396,956 shares of the company’s stock worth $3,827,000 after acquiring an additional 109,747 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its stake in shares of Enhabit by 2,977.5% in the 2nd quarter. Lazard Asset Management LLC now owns 86,200 shares of the company’s stock valued at $830,000 after purchasing an additional 83,399 shares in the last quarter.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.